EAM
Erste Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.35M | Buy |
26,700
+2,900
| +12% | +$364K | 0.03% | 326 |
|
|
2025
Q1 | $2.69M | Hold |
23,800
| – | – | 0.03% | 275 |
|
|
2024
Q4 | $3.32M | Hold |
23,800
| – | – | 0.04% | 274 |
|
|
2024
Q3 | $2.74M | Hold |
23,800
| – | – | 0.03% | 286 |
|
|
2024
Q2 | $3.2M | Hold |
23,800
| – | – | 0.04% | 269 |
|
|
2024
Q1 | $3.28M | Hold |
23,800
| – | – | 0.04% | 264 |
|
|
2023
Q4 | $3.15M | Hold |
23,800
| – | – | 0.05% | 259 |
|
|
2023
Q3 | $2.74M | Hold |
23,800
| – | – | 0.05% | 249 |
|
|
2023
Q2 | $2.25M | Hold |
23,800
| – | – | 0.04% | 276 |
|
|
2023
Q1 | $2.36M | Hold |
23,800
| – | – | 0.05% | 277 |
|
|
2022
Q4 | $2.86M | Hold |
23,800
| – | – | 0.06% | 251 |
|
|
2022
Q3 | $2.45M | Hold |
23,800
| – | – | 0.05% | 265 |
|
|
2022
Q2 | $2.34M | Hold |
23,800
| – | – | 0.05% | 275 |
|
|
2022
Q1 | $2.2M | Sell |
23,800
-1,100
| -4% | -$102K | 0.04% | 284 |
|
|
2021
Q4 | $2.1M | Hold |
24,900
| – | – | 0.04% | 293 |
|
|
2021
Q3 | $2.35M | Hold |
24,900
| – | – | 0.05% | 262 |
|
|
2021
Q2 | $2.41M | Hold |
24,900
| – | – | 0.05% | 268 |
|
|
2021
Q1 | $2.35M | Hold |
24,900
| – | – | 0.06% | 252 |
|
|
2020
Q4 | $2.34M | Sell |
24,900
-14,800
| -37% | -$1.39M | 0.06% | 246 |
|
|
2020
Q3 | $3.88M | Hold |
39,700
| – | – | 0.13% | 174 |
|
|
2020
Q2 | $4.98M | Hold |
39,700
| – | – | 0.2% | 133 |
|
|
2020
Q1 | $3.64M | Sell |
39,700
-75,000
| -65% | -$6.87M | 0.21% | 125 |
|
|
2019
Q4 | $12.3M | Buy |
114,700
+18,000
| +19% | +$1.94M | 0.55% | 50 |
|
|
2019
Q3 | $8.72M | Sell |
96,700
-8,000
| -8% | -$721K | 0.46% | 58 |
|
|
2019
Q2 | $8.76M | Sell |
104,700
-1,000
| -0.9% | -$83.7K | 0.47% | 57 |
|
|
2019
Q1 | $9.21M | Sell |
105,700
-15,200
| -13% | -$1.32M | 0.52% | 43 |
|
|
2018
Q4 | $8.44M | Buy |
+120,900
| New | +$8.44M | 0.57% | 40 |
|